CAS: 51333-22-3; Budesonide

上下游产品

21-乙酰氧基-11Beta-羟基-16Alpha,17Alpha-丙基甲基烯二氧代孕甾烷-1,4-二烯-3,20-二酮 2-((6Ar,6Bs,7S,8As,8Bs,11Ar,12As,12Bs)-7-Hydroxy-6A,8A-Dimethyl-4-Oxo-10-Propyl-2,4,6A,6B,7,8,8A,8B,11A,12,12A,12B-Dodecahydro-1H-Naphtho[2',1':4,5]Indeno[1,2-D][1,3]Dioxol-8B-yl)-2-Oxoethyl Acetate 51333-05-2
地索奈德 Desonide 638-94-8
16Alpha-羟基泼尼松龙 Desonide 13951-70-7
二羟基孕甾-1,4,9(11)三烯-3,20-酮-21-醋酸酯 21-Acetoxy-16α,17α-Dihydroxy-1,4,9(11)-Pregnatrien-3,20-Dion 77017-20-0
醋酸泼尼松龙 Prednisolone 21-Acetate 52-21-1

2-((10S,13S)-10,13-Dimethyl-3-Oxo-6,7,8,10,12,13,14,15-octahydro-3H-Cyclopenta[a]Phenanthren-17-yl)-2-Oxoethyl Acetate置于盐酸,Potassium Permanganate,N-溴代丁二酰亚胺(Nbs),甲酸,高氯酸,Chromium(Iii) Chloride Hexahydrate,巯基乙酸,Sodium Hydroxide,锌体系中,用 四氢呋喃,甲醇,二氯甲烷,水,N,N-二甲基甲酰胺,丙酮,乙腈 作为反应溶剂,化学反应 7.0H,反应生成 左布地奈德
参考文献:一种布地奈德工业化制备方法
标题:一种布地奈德工业化制备方法
摘要:本发明涉及一种布地奈德工业化制备方法.具体而言,本发明涉及在盐酸水溶液,二氯甲烷和乙腈中,16α‑羟基泼尼松龙与正丁醛反应制得布地奈德.本发明的方法具有在工业上可实施,重现性好等优势.

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-9315483-B2
优先权日:2007-09-13
标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
发明人：JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT
权利人:CONCERT PHARMACEUTICALS INC
摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.

专利号:US-11311505-B2
优先权日:2017-02-24
标 题:Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人：MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:US-10813893-B2
优先权日:2017-02-24
标 题:Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:The present invention has shown that not all salts of pyruvic acid enhance lung functions or enhance the synthesis of lung surfactants and that certain salts of pyruvic acid with the correct concentrations of calcium, phosphate and magnesium, are synergistic in their ability to enhance the synthesis of lung surfactants that will enhance lung alveoli functions, while decreasing coughing and lung tightness, and increasing oxygen saturation values to prevent hypoxemia. This patent demonstrates that the sodium pyruvate formula with calcium, phosphate and magnesium was superior over standard sodium pyruvate formula in saline alone in the removal of mucus, reduction of lung or sinus infections, and in reducing drug side effects and congestion. The use of this formula clearly demonstrated that it can be used to produce better efficacy in patients with hypoxemia, with lung and sinus diseases including, asthma, COPD, cystic fibrosis, interstitial lung disease, allergic rhinitis, sinusitis, Alzheimer's, disease, Parkinson's disease, brain trauma, nicotine addiction, sleep apnea, autism, migraine headaches, sleep disorders, lung and sinus infections, cancer therapy with cancer drugs, nicotine addiction, and medications that cause a decrease in lung surfactants.